PNAS: The new findings help develop the COVID19 vaccine.

26 July 2020 // --- According to a study by the Emory Vaccine Center, a vaccine additive can enhance the body's response to the avian influenza virus H5N1 vaccine, thereby enhancing the immune response.
discovery is important for efforts to develop a vaccine for a variety of influenza strains and for the current push for the SARS-CoV-2 vaccine.
the study provides guidance on how adjorizers can become part of a "universal" influenza vaccine, which is designed to protect people from a wide variety of flu strains.
, vaccine designers are considering how to optimize the immune response to SARS-Cov-2.
results were published in the recent pNAS journal. "No one has an immunity to new pathogens like SARS-CoV-2," said the author of
(photo source: www.pixabay.com).
it is therefore important that the vaccine produce a good response from less frequent natural B cells.
the situation is more complicated for influenza.
because of the need to produce both cross-reactive memory cells and natural blocking-specific cells," he said.
author Ahmed's lab is located in the National Institutes of Health system.
a special adjugate called AS03, which glaxoSmithKline, the manufacturer, is using in the COVID-19 vaccine trial.
Ahmed said AS03 adjorrs may be related to the efficacy of expanding a limited dose of protein or viral sub-vaccines, but less important for mRNA-based vaccines.
study recruited 50 healthy young people who were likely to have been exposed to other influenza viruses and vaccines early in their lives.
H5N1 vaccine with AS03 was approved by the FDA in 2013 and is used to fight the flu outbreak.
Emory researchers have previously observed that when the immune system encounters an unfamiliar influenza virus that occurs during the 2009 H1N1 pandemic, the resulting antibodies can neutralise the wider virus.
this is due to the fact that antibodies tend to the "stem" area of the viral hemagglutinin protein rather than the "head". The
stem area is relatively conservative.
but with the aid of adjour, the immune response changes significantly between the first and second doses.
a week after the first intake, the extensive cross-reaction antibodies produced by the immune system were mostly produced in the stem region. the first wave of
comes mainly from pre-existing memory B cells.
the second injection, the antibody is more directed at the head, coming from specific natural B cells.
(bioon.com) Information Source: Findings Show for Development Vaccines Vs. Multipletrains of flu, the original source of the series: Ellebedy, A. H. Specific, et al. (2020) Adjuvanted H5N1. Proceedings of the National Academy of Sciences. doi.org/10.1073/pnas.1906613117.